Composition
- Active ingredients
- ALISKIREN HEMIFUMARATE EQ 300MG BASE; AMLODIPINE BESYLATE EQ 5MG BASE
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- ALISKIREN HEMIFUMARATE EQ 300MG BASE; AMLODIPINE BESYLATE EQ 5MG BASE · TabletThis page
- ALISKIREN HEMIFUMARATE EQ 150MG BASE; AMLODIPINE BESYLATE EQ 5MG BASE · TabletNDA022545-001 · Discontinued
- ALISKIREN HEMIFUMARATE EQ 300MG BASE; AMLODIPINE BESYLATE EQ 10MG BASE · TabletNDA022545-004 · Discontinued
- ALISKIREN HEMIFUMARATE EQ 150MG BASE; AMLODIPINE BESYLATE EQ 10MG BASE · TabletNDA022545-002 · Discontinued
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA022545.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Tekamlo
- Active substance
- aliskiren hemifumarate
- Route
- Oral
- Dosage form
- Tablet
- Applicant
- Novartis
- Status
- Discontinued
- FDA approval
- 26 Aug 2010
- Application
- NDA022545-003